CVS Health Misses 2026 Profit Forecast, Shares Drop
CVS Health falls short of Wall Street's 2026 profit expectations despite beating Q4 estimates. Stock drops 3% as company maintains cautious outlook amid healthcare industry challenges.
CVS Health falls short of Wall Street's 2026 profit expectations despite beating Q4 estimates. Stock drops 3% as company maintains cautious outlook amid healthcare industry challenges.
FDA issues Complete Response Letter rejecting RGX-121 gene therapy for Hunter syndrome, citing trial design concerns. Regenxbio plans to resubmit with additional data.
Wedbush gives Zura Bio an Outperform rating and $15 target, highlighting upcoming clinical catalysts and potential stock growth through 2026.
Danish pharma giant Novo Nordisk files patent lawsuit against telehealth company Hims & Hers for selling unauthorized versions of Wegovy and Ozempic weight-loss medications.
Eli Lilly acquires Orna Therapeutics to advance groundbreaking in vivo CAR-T therapies for autoimmune diseases using circular RNA technology.
Wells Fargo upgrades GeneDx to Overweight, saying the recent stock decline looks excessive and growth opportunities could drive momentum into 2026.